Study of Qishenyiqi Dripping Pill for Treating Coronary Microvascular Disease Evaluating Effects on Chest Pain and Heart Blood Flow Over One Year

What this Trial Is About

Researchers are studying the effectiveness and safety of Qishenyiqi dripping pills for patients with coronary microvascular disease, a condition causing chest pain due to small vessel problems in the heart. This Phase 4 trial will follow patients for one year to assess how the treatment affects coronary blood flow and cardiovascular events in those with this disease. The trial is randomized and quadruple-blinded to carefully compare Qishenyiqi with a placebo. Participants will be randomly assigned to receive either Qishenyiqi dripping pills or a placebo, each taken as one bag three times daily for 12 months. The study includes a long-term follow-up period of one year to observe changes in coronary flow reserve and any adverse cardiovascular events. Treatments are administered orally and monitored throughout the study period. During the trial, participants will have their coronary flow reserve measured by three-dimensional echocardiography at the start and after 12 months to evaluate heart blood flow changes. Researchers will monitor safety and cardiovascular outcomes over the year, tracking chest pain episodes and other heart-related events. Participants can expect regular assessments and follow-up visits throughout the study duration.

Qishenyiqi Dripping Pill for Coronary Microvascular Disease